Amgen has now answered Coherus BioSciences’ complaint and denies that it has infringed on Coherus’ patents. Amgen also said that the patents are invalid for failure to comply with requirements of the law.
In a complaint filed earlier this year, biosimilar developer Coherus BioSciences alleged that Amgen, maker of the EU-authorized and marketed Amgevita, a biosimilar adalimumab, has infringed on a number of Coherus’ patents directed to the stable formulation of adalimumab.
According to Coherus’ original complaint, manufacture of the EU-marketed Amgevita in the United States constitutes infringement on 3 of its US patents, and this infringement warrants an award of damages.
Later, Coherus amended its complaint to include alleged infringement of a fourth patent, also directed to the stable aqueous pharmaceutical composition of adalimumab.
Amgen has now answered Coherus’ complaint, and denies that it has infringed on Coherus’ patents. Amgen also said that the patents are invalid for failure to comply with requirements of the law.
According to Amgen, Coherus “had to deceive the United States Patent and Trademark Office” in order to procure patents that had claims to anticipated and obvious adalimumab formulations. The Amgevita-maker’s response states that the patents’ inventor and Coherus’ attorney together withheld material prior art and other information from the office, and says that these parties misstated material facts with the intention to deceive.
Amgen’s response goes on to say that the inventor and attorney filed multiple petitions for inter partes review (IPR) against claims of patents held by AbbVie (maker of the brand-name adalimumab, Humira), and that these petitions took positions that were directly contrary to those taken in their own applications for patents.
Amgen says these positions were material to the patentability of the claims at issue in Coherus’ complaint, and the existence of these IPR challenges, says Amgen, were not disclosed to the patent office. Disclosure of these issues, says Amgen, could have changed which claims of the asserted patents that the office would have allowed.
Coherus also withheld material prior art references, says Amgen, including the most pertinent prior art from AbbVie’s portfolio of adalimumab patents. However, other, less relevant patents in the same family were submitted. “The single most reasonable inference to be drawn,” says Amgen’s response, is that Coherus’ agents “acted with the intention of deceiving the Patent Office and procuring the Asserted Patents on the basis of an incomplete and/or misleading record.”
Amgen seeks a trial by jury, and has asked the court to deny all forms of relief to Coherus, dismiss Coherus’ complaint, declare that Amgen has not infringed the patents, and declare the patents invalid and unenforceable.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).